In the past week, BPTH stock has gone down by -11.29%, with a monthly decline of -26.89% and a quarterly plunge of -39.58%. The volatility ratio for the week is 11.12%, and the volatility levels for the last 30 days are 8.76% for Bio-Path Holdings Inc The simple moving average for the past 20 days is -17.65% for BPTH’s stock, with a -71.21% simple moving average for the past 200 days.
Is It Worth Investing in Bio-Path Holdings Inc (NASDAQ: BPTH) Right Now?
The 36-month beta value for BPTH is also noteworthy at 0.26. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BPTH is 3.71M, and at present, short sellers hold a 10.48% of that float. The average trading volume of BPTH on November 07, 2024 was 1.41M shares.
BPTH) stock’s latest price update
Bio-Path Holdings Inc (NASDAQ: BPTH) has experienced a decline in its stock price by -11.18 compared to its previous closing price of 0.98. However, the company has seen a fall of -11.29% in its stock price over the last five trading days. globenewswire.com reported 2024-10-10 that HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of an aggregate of 4,597,702 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 6,407,657 shares of common stock and short-term series B warrants to purchase up to 6,407,657 shares of common stock at a purchase price of $0.87 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement. The series A warrants and short-term series B warrants have an exercise price of $1.00 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”). The series A warrants will expire five years from the Stockholder Approval Date and the short-term series B warrants will expire twenty-four months from the Stockholder Approval Date.
Analysts’ Opinion of BPTH
Many brokerage firms have already submitted their reports for BPTH stocks, with ROTH Capital repeating the rating for BPTH by listing it as a “Buy.” The predicted price for BPTH in the upcoming period, according to ROTH Capital is $13 based on the research report published on March 11, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see BPTH reach a price target of $1.50, previously predicting the price at $4.50. The rating they have provided for BPTH stocks is “Buy” according to the report published on November 13th, 2017.
Maxim Group gave a rating of “Buy” to BPTH, setting the target price at $2 in the report published on August 10th of the previous year.
BPTH Trading at -12.76% from the 50-Day Moving Average
After a stumble in the market that brought BPTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.65% of loss for the given period.
Volatility was left at 8.76%, however, over the last 30 days, the volatility rate increased by 11.12%, as shares sank -20.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.01% lower at present.
During the last 5 trading sessions, BPTH fell by -11.29%, which changed the moving average for the period of 200-days by -89.42% in comparison to the 20-day moving average, which settled at $1.0564. In addition, Bio-Path Holdings Inc saw -90.60% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BPTH
Current profitability levels for the company are sitting at:
- -47.6 for the present operating margin
- 0.39 for the gross margin
The net margin for Bio-Path Holdings Inc stands at -42.32. The total capital return value is set at -6.19. Equity return is now at value -366.18, with -199.23 for asset returns.
Based on Bio-Path Holdings Inc (BPTH), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -161.11. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -686.42.
Currently, EBITDA for the company is -15.76 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of -2.64. The receivables turnover for the company is -1.0for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
In summary, Bio-Path Holdings Inc (BPTH) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
